NBIX (Neurocrine Biosciences) Enterprise Value : $12,281 Mil (As of Jul. 05, 2025) ***

Neurocrine Biosciences Enterprise Value Chart

Neurocrine Biosciences Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Enterprise Value		Get a 7-Day Free Trial					8,573.28	7,811.73	10,799.56	12,401.51	12,947.10

Neurocrine Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Enterprise Value	Get a 7-Day Free Trial															13,173.29	13,108.20	10,683.66	12,947.10	10,446.54

Competitive Comparison of Neurocrine Biosciences's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurocrine Biosciences's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Enterprise Value falls into.

Neurocrine Biosciences Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Neurocrine Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as

Neurocrine Biosciences's Enterprise Value for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences  (NAS:NBIX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Neurocrine Biosciences's EV-to-EBIT for today is

Neurocrine Biosciences's current Enterprise Value is $12,281 Mil.
Neurocrine Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $531 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Neurocrine Biosciences's EV-to-EBITDA for today is:

Neurocrine Biosciences's current Enterprise Value is $12,281 Mil.
Neurocrine Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $560 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Neurocrine Biosciences's EV-to-Revenue for today is:

Neurocrine Biosciences's current Enterprise Value is $12,281 Mil.
Neurocrine Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,413 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Neurocrine Biosciences's EV-to-FCF for today is:

Neurocrine Biosciences's current Enterprise Value is $12,281 Mil.
Neurocrine Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $492 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Enterprise Value Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences Business Description